ARGENX Receives FDA Priority Review for VYVGART sBLA in Seronegative gMG, Targeting Expanded Patient Population
ARGX sits 59% above its 52-week low of $510.055.
Summary
ARGENX announced the FDA has granted priority review for its supplemental Biologics License Application for VYVGART in AChR-Ab seronegative generalized myasthenia gravis, with a PDUFA date of May 10, 2026.
Key Events · Product Development and Regulatory · ARGX
-
FDA Accepts sBLA with Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART (efgartigimod alfa-fcab) for the treatment of adults with AChR-Ab seronegative generalized myasthenia gravis (gMG).
-
PDUFA Target Action Date Set
A Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026, has been set for the sBLA.
-
Supported by Positive Phase 3 Data
The sBLA is supported by data from the Phase 3 ADAPT SERON study, which met its primary endpoint, demonstrating statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score compared to placebo.
-
Addresses Unmet Medical Need
This expanded indication aims to provide a much-needed treatment option for seronegative gMG patients, who currently face limited therapeutic choices.
Analysis · ARGX · Life Sciences
The FDA's acceptance of the supplemental Biologics License Application (sBLA) for VYVGART with Priority Review is a significant positive development for ARGENX. This accelerates the potential approval timeline for an expanded indication, addressing a critical unmet medical need in acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG) patients. The positive Phase 3 ADAPT SERON study data supporting the sBLA further de-risks the approval process and positions VYVGART to capture a broader market segment, potentially driving future revenue growth for the company.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARGX was trading at $813.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.5B. The 52-week trading range was $510.06 to $934.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.